On the other hand, FXa-inhibitor landmark trials have reported numerically fewer myocardial infarctions compared with warfarin [38,39,40,41], and basic science studies have investigated potential mechanisms for this apparently protective effect, with discrepant results [5,20,42]. The gene discussed is F10; the disease is myocardial infarction.